Dr. Markowitz will work closely with other scientific and development leaders on portfolio evaluation and decision making as well as assessing external opportunities.
"Regeneron stands out as a company with a robust, diverse pipeline and a deep productive scientific and technological engine," said Dr. Markowitz. "I am thrilled to join this great team that is advancing important and promising potential treatments for people with a number of serious diseases."
Prior to Capital World Investors, Dr. Markowitz was a biotechnology analyst and portfolio manager at T. Rowe Price. Before transitioning to an investment career, he was an assistant professor and transplant surgeon at the Johns Hopkins University School of Medicine.
Dr. Markowitz received his undergraduate degree from Columbia University and his M.D. from Duke University. He completed a fellowship in transplant surgery at the UCLA Medical Center, a surgical residency at Massachusetts General Hospital, and a Research Fellowship in Cellular and Molecular Immunology at the Harvard School of Public Health.
About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL cholesterol and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, atopic dermatitis, asthma, pain, cancer and infectious diseases. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
Media Contact at Regeneron:
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/regeneron-hires-jay-markowitz-md-as-senior-vice-president-of-portfolio-management-300384813.html
SOURCE Regeneron Pharmaceuticals, Inc.